Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q2 EPS of ($0.13), $0.04 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $81.5 million versus the consensus estimate of $73.25 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.